



5835 Peachtree Corners East, Suite D
Norcross, GA 30092

Contact

Media: Bill Wells – 770-242-8723

Guided Therapeutics' Stock Moves Up From Pink Sheets to OTC Bulletin Board

Norcross, GA (June 11, 2010) -- Guided Therapeutics, Inc. ([OTCBB: GTHP](#)) today announced that its stock is now trading on the OTCBB under the symbol GTHP, following approval of the listing by the Financial Industry Regulatory Authority (FINRA).

“Listing our stock on the OTCBB is an important milestone for the company as we continue to build value for our shareholders,” said Mark L. Faupel, Ph.D., chief executive officer and president of Guided Therapeutics. “The listing is one in a series of recent positive events for the company that includes significantly reducing our debt, strengthening our board of directors, simplifying our capital structure and maintaining current filer status with the Securities and Exchange Commission.”

About Guided Therapeutics

Guided Therapeutics, Inc. ([OTCBB: GTHP](#)) is developing a rapid and painless test for the early detection of disease that leads to cervical cancer. The technology is designed to provide an objective result at the point of care thereby improving the management of cervical disease. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are known immediately. GT has also entered into a partnership with Konica Minolta Opto to develop a non-invasive test for Barrett's Esophagus using the LightTouch™ technology platform. For more information, visit GT's web site www.guidedinc.com.

The Guided Therapeutics LightTouch™ Cervical Scanner is an investigational device and is limited by federal law to investigational use.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-KA for the fiscal year ended December 31, 2009 and subsequent quarterly reports.

###END###